Shattuck Labs

Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. It primarily focuses on Agonist Redirected Checkpoint (ARC) and Gamma Delta T Cell Engagers (GADLEN) platforms. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Shattuck Labs reports Q4 losses, optimistic for 2023 advancements

Shattuck Labs showcased progress with lead program 154 and a strong financial position.
Challenges include discontinued program SL-279252 and financial losses in 2022.
Opportunities lie in ongoing clinical trials, differentiation between programs, and optimism for 2023.

Shattuck Labs reports promising Q3 results and eyes future milestones

Shattuck Labs (STTK) showcased progress with SL-172154 in Q3 2023, reporting promising clinical data and a strong financial position. While facing challenges of ongoing losses, the company's unique mechanism of action and upcoming milestones present opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call on initial data from its ongoing frontline expansion cohorts in HR-MDS and TP53m AML and review data from the poster presentation featured at the 65th ASH Annual Meeting on Wednesday, December 13, 2023 at 8:00 a.m. ET.

Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Da

AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 6th Annual Evercore ISI HealthCONx Conference being held November 28-30, 2023.

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Conor Richardson – Vice President-Investor Relations Taylor Schreiber – Scientific Co-Founder and Chief Executive Officer Lini Pandite – Chief Medical Officer Andrew Neill – Chief Financial Officer Conference Call Participants Jonathan Miller – Evercore ISI Joe Pantginis – H.C. Wainwright Marc Frahm – TD Cowen Yigal Nochomovitz – Citi Gil Blum – Needham & Company Operator Good morning and welcome to the Shattuck Labs Third Quarter 2023 Earnings Conference Call.

Shattuck Labs, Inc. (STTK) Q3 2023 Earnings Call Transcript

– Positive interim data from Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safety profile and encouraging anti-tumor activity that compares favorably to PLD as a monotherapy; expect to complete enrollment in this expansion cohort in the fourth quarter of 2023 –

Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights

AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023.

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile –

Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annua

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.

Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates

– Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting, including data supporting 3 mg/kg as the appropriate dose for each PROC combination cohort –

Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose –

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.58 per share a year ago.

Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates

— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in June –

Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights

Esperion Therapeutics

Verastem

Banco Bradesco

Tritium DCFC Ltd

ESS Tech

Momentus

Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.

7 Very Undervalued Penny Stocks to Buy in April 2023

AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 22nd Annual Needham Virtual Healthcare Conference being held April 17-20, 2023.

Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference

– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease –

Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Shattuck Labs, Inc. (NASDAQ:STTK ) Q4 2022 Earnings Conference Call February 23, 2023 4:45 PM ET Company Participants Conor Richardson - Vice President, Investor Relations Taylor Schreiber - Chief Executive Officer and Scientific Co-Founder Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore ISI Marc Frahm - Cowen Yigal Nochomovitz - Citi Zhiqiang Shu - Berenberg Operator Good afternoon, ladies and gentlemen. Welcome to the Shattuck Labs Fourth Quarter and Full Year 2022 Earnings Conference Call.

Shattuck Labs, Inc. (STTK) Q4 2022 Earnings Call Transcript

– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its fourth quarter and full year 2022 financial results and provide a general business overview on Thursday, February 23, 2023.

Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023

AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference being held virtually February 13-16, 2023.

Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference

AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2023.

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023

After losing some value lately, a hammer chart pattern has been formed for Shattuck Labs, Inc. (STTK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Conor Richardson - Senior Director of Finance and Investor Relations Taylor Schreiber - Chief Executive Officer Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Gil Blum - Needham & Company Carly Kenselaar - Citi Kaveri Pohlman - BTIG Zhiqiang Shu - Berenberg Operator Good afternoon, everyone, and welcome to Shattuck Labs Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Shattuck Labs, Inc. (STTK) Q3 2022 Earnings Call Transcript

– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 –

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the treatment of cancer -

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three investor conferences in November 2022.

Shattuck Labs Announces Participation in Upcoming November Conferences

AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.

News for Shattuck Labs Stock (STTK)